“And by the end of the year, we’ll have -- the uncertain will be removed almost largely.”

In context

“p patients between the ages of 2 and 3 years old, 10 patients enrolled in that trial. So yes, we’re looking forward to share the data later this year for you. Dr. Albert Bourla: Thank you very much. In summary, I think we had a solid quarter. Continue to invest to support our unprecedented 19 potential launches in an 18-month period. These are doing very well. The plan is executed as the time lines, in our pipeline and in value-creating revenue-generating business development opportunities like Seagen, which, as I articulated just in the question before that, it is clearly our big bet and our very, very big opportunity moving forward. Over the next three months, we look forward to moving beyond the current uncertainty related to our COVID-19-related revenue. So, we’ll have better clarity. And by the end of the year, we’ll have -- the uncertain will be removed almost largely. To that extent, but any adjustments to our cost base for ‘24 and beyond, we are ready to make. I want to reemphasize that the biggest uncertainty in terms of the long term is vaccination rate, some shorter uncertainties like when commercialization will be, I think it’s just a question of time. But the vaccination and treatment rates that we are going to see, I think, will inform what is -- what we should expect for the years to come, with only upside if we the combination vaccines. Putting all these factors together, we remain confident in our ability to deliver a robust operational growth and deliver meaningful shareholder value through the end of the decade and beyond. And now, we will bring our call to a close. Thank you for joining us, and have a great rest of your day. Operator: Than”